Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Adicionar filtros








Intervalo de ano
1.
Journal of Prevention and Treatment for Stomatological Diseases ; (12): 820-827, 2021.
Artigo em Chinês | WPRIM | ID: wpr-886564

RESUMO

Objective@#Systematic evaluation of the correlation of HLA-DQB1 and HLA-DRB1 allele polymorphisms with caries, to provide reference for caries prevention and treatment. @*Methods@# Relevant literature published before December 2020 was searched in the Cochrane Library, PubMed, Embase, Web of Science, Scopus, CNKI, Wanfang, VIP, and CBM databases. Meta-analysis was performed using the R4.0.2 software to test for heterogeneity and evaluate the publication bias.@*Results @# In total,10 case-control studies were included with 564 people in the case group and 676 people in the control group. The results of the Meta-analysis show that: ① HLA-DQB1*02 (OR=0.52, 95%CI=0.29-0.93, P < 0.05) and HLA-DRB1*09 (OR=0.34, 95%CI=0.21-0.58, P < 0.05) are protective factors of dental caries; ② HLA-DRB1*13 (OR=2.96, 95%CI=2.03-4.33, P < 0.05) and HLA-DRB1*14 (OR=1.95, 95%CI=1.26-3.02, P < 0.05) alleles are risk factors for the development of dental caries. The results of the subgroup analysis are: HLA-DRB1*07 is a caries susceptibility factor in the Chinese population (OR=0.48, 95% CI=0.24-0.97, P < 0.05), while it is not statistically significant in the Brazilian and Turkish populations; HLA-DRB1*11 is a caries protective factor in the saliva group (OR=2.26, 95% CI=1.46-3.52, P < 0.05). 3.52, P < 0.001), while it is a caries susceptibility factor in the blood group (OR=0.09, 95% CI=0.12-0.34, P < 0.001). @*Conclusion @#HLA-DRB1*13 and HLA-DRB1*14 alleles are caries susceptibility genes, and HLA-DQB1*02 and HLA-DRB1*09 have protective effects on the caries development. HLA-DRB1*07 is a caries susceptibility gene in the Chinese population; HLA-DRB1*11 is a caries protective gene in the saliva group. Due to the limited sample size and quality of the included studies, more high-quality studies will be included later for verification.

2.
Journal of Prevention and Treatment for Stomatological Diseases ; (12): 809-819, 2021.
Artigo em Chinês | WPRIM | ID: wpr-886563

RESUMO

Objective@#To explore the potential mechanism of the main active component Tripterygium wilfordii in the treatment of oral lichen planus based on network pharmacology.@*Methods@#The components of Tripterygium wilfordii and targets were searched through the Traditional Chinese Medicine system pharmacology database and analysis platform (TCMSP) and the Traditional Chinese Medicine integrated database (TCMID) databases. The related targets of oral lichen planus (OLP) were obtained through databases such as Gene Cards. The OLP targets were mapped by Venn analysis to the targets of Tripterygium wilfordii to screen out the common targets as the treatment of OLP targets of Tripterygium wilfordii. The Cytoscape software and STRING were used to construct a chemical component-target network and protein-protein interaction network, a network analyzer was used to compute the network topology properties, a cluster profiler software was used to analyze the GO classification enrichment analysis and KEGG signal path analysis, and a Tripterygium wilfordii chemical components-targets-pathway network diagram was constructed. @*Results@#Twenty-three components and 44 OLP treatmenttargets of Tripterygium wilfordii were obtained. The key active ingredients of Tripterygium wilfordii in the treatment of OLP are triptolide, kaempferol, and tangerine peel. The key targets include TNF and AKT1. The GO classification enrichment analysis obtained 63 GO terms, which are mainly involved in the leukocyte differentiation and reaction to lipopolysaccharides. The KEGG analysis identified 111 signaling pathways, which are mainly related to the TNF signaling pathway and IL17 signaling pathway. @*Conclusion@#Tripterygium wilfordii in the treatment of OLP. This study can provide a theoretical basis for further research to explore drugs with high activity and low toxicity to treat OLP from Tripterygium wilfordii.

3.
J Cancer Res Ther ; 2020 Sep; 16(5): 960-966
Artigo | IMSEAR | ID: sea-213740

RESUMO

As a treatment option for cancer, thermal ablation has satisfactory effects on many types of solid tumors (such as liver and renal cancers). However, its clinical applications for the treatment of thyroid nodules and metastatic cervical lymph nodes are still under debate both in China and abroad. In 2015, the “Zhejiang Expert consensus on thermal ablation for thyroid benign nodules, microcarcinoma, and metastatic cervical lymph nodes (2015 edition),” was released by the Thyroid Cancer Committee of Zhejiang Anti-Cancer Association, China. To further standardize the application of thermal ablation for thyroid tumors, the Thyroid Tumor Ablation Experts Group of Chinese Medical Doctor Association has organized many seminars and finally produced a consensus to formulate the “Expert consensus workshop report: Guidelines for thermal ablation of thyroid tumors (2019 edition).”

4.
Journal of Prevention and Treatment for Stomatological Diseases ; (12): 451-456, 2019.
Artigo em Chinês | WPRIM | ID: wpr-750566

RESUMO

Objective@#To compare the apical sealing effects of two root canal fillers, GuttaFlow and AH Plus, for clinical reference.@* Methods@#The Cochrane system evaluation method was used to search the Cochrane Library, Embase, CBM, PubMed, CNKI, Weipu, and Wanfang databases. Additionally, relevant journals and conference papers were manually retrieved, and relevant randomized controlled trials were collected. Two reviewers independently evaluated the quality of each study and extracted the data. A meta-analysis was performed using the RevMan5.3 software for homogenous studies, and a descriptive analysis was performed for studies with poor homogeneity.@*Results@#In total, 10 randomized controlled trials containing 398 isolated teeth were included. The meta-analysis results showed that the difference in apical microleakage was statistically significant at 1 week and 3 months [1 week: MD=-0.13, 95% CI (-0.22,-0.04), P=0.007; 3 months: MD=-1.27, 95% CI (-1.94,-0.60), P=0.000 2] but not at 6 months [MD=-0.10, 95% CI (-0.26, 0.06), P=0.23].@* Conclusion@#Based on existing research results, GuttaFlow may achieve better results than AH Plus in the short term (≤ 1 week). Because it is subject to limitations of time, quality, and research methods, this conclusion requires more long-term, high-quality, large-sample, multimeasurement randomized controlled trials for further validation.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA